Jefferies Comments On NuVasive 1Q Results

According to Jefferies, NuVasive NUVA reported a 1Q result that beat on both revenue and earnings. Jefferies said that the revenue beat was driven by better performance out of the core lumbar business; the EPS beat was mostly non-operational. “The spine market remains challenging, but the outlook appears to be stabilizing. NUVA is exceeding its targets and guidance remains readily achievable. Reiterate Buy.” NuVasive closed yesterday at $30.60.